|
市場調查報告書
強迫症：小規模市場之市場機會的最大化策略
Obsessive-Compulsive Disorder: Strategies to Maximize Opportunities in a Small Market
|
強迫症：小規模市場之市場機會的最大化策略 是由出版商Decision Resources, Inc.在2008年05月所出版的。
這份英文市場調查報告書包含24 Pages 價格從美金2250起跳。
本報告書內容包括：強迫症發病人數現況及預測（美國・至2017年）、病因、流行病學調查分析、一般應用於強迫症治療中的治 療藥、強迫症市場的發展潛力最大化策略、市場中企業的市場佔有率資料（美國）等。內容綱要摘記如下：
實施概要
介紹
強迫症概要
現在的治療藥
- 治療規則
- 經FDA許可的治療藥
- Eli Lilly的Prozac
- GlaxoSmithKline的Paxil
- Pfizer的Zoloft
- Novartis的Anafranil
- 未經許可藥品之利用
- Forest Laboratories的Lexapro
- SNRI
- Benzodiazepines
- 非定型抗精神病藥
美國市場：2007年
強迫症市場的發展潛力最大化
圖表
Abstract
Introduction
Although the obsessive-compulsive disorder (OCD) market is small and OCD
diagnosis rates are low, this market is characterized by substantial unmet
need and commercial opportunity. Companies looking to expand their agents into
this market need to explore unconventional strategies that will minimize the
resources necessary to ensure success in OCD.
Get the Answers You Need to Shape Your Strategy
- Despite the high use of drug therapy in the treatment of OCD, 40-60% of
patients do not achieve suffi cient relief from their symptoms. What
opportunities does this unmet need present to developers? Are any agents now
in development likely to meet this need?
- Due to the large percentage of patients who are not suffi ciently treated
with available approved agents, psychiatrists often prescribe off-label agents
to treat OCD. How well do these off-label agents perform in the OCD market?
Will pending guidance from the FDA regarding the distribution of data from
clinical trials in off-label indications help companies increase their market
share for off-label treatments?
- Although there are few agents in commercial development for OCD, there are
agents being investigated for their effi cacy in OCD by research and medical
organizations. What does the possible infl ux of a large number of new
agents to treat OCD mean for currently available treatments? How can emerging
agents differentiate themselves from other current and emerging agents?
Scope
- Overview of OCD: symptoms and diagnosis, etiology.
- Epidemiology: Decision Resources estimates of the number of
prevalent cases of OCD in the major markets over 2007-2017 and the number of
diagnosed and drug-treated cases in the major markets in 2007.
- Treatment algorithms: a treatment decision tree, a listing of
currently used agents, and profi les of leading agents.
- Use of off-label agents: discussion of agents commonly used
off-label, physician attitudes toward off-label use, pending FDA proposals to
broaden marketing of these agents.
- OCD market: 2007 sales fi gures, current market dynamics,
strategies for maximizing market potential.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Obsessive-Compulsive Disorder
- Disease Diagnosis and Symptoms
- Etiology
- Epidemiology
- Current Treatments for Obsessive-Compulsive Disorder
- Treatment Algorithm for Obsessive-Compulsive Disorder
- FDA-Approved Treatments for Obsessive-Compulsive Disorder
- Eli Lilly' s Prozac
- GlaxoSmithKline' s Paxil
- Pfi zer' s Zoloft
- Novartis' s Anafranil
- Drugs Used Off-Label to Treat Obsessive-Compulsive Disorder
- Forest Laboratories' Lexapro
- SNRIs
- Benzodiazepines
- Atypical Antipsychotics
- 2007 U.S. Market
- Maximizing the Potential of the Obsessive-Compulsive Disorder Market
- Current Dynamics of the Obsessive-Compulsive Disorder Market
- Strategies for the Obsessive-Compulsive Disorder Market
- Pediatric Approval
- Small Clinical Trials
Tables:
- 1. Agents Commonly Used to Treat Obsessive-Compulsive Disorder
- 2. U.S. Obsessive-Compulsive Disorder Market, 2007
- 3. Agents Approved for Other Indications Being Investigated for Effi cacy
in Obsessive-Compulsive Disorder, 2008
Figures:
- 1. Total Prevalent Cases of Obsessive-Compulsive Disorder in the United
States, Europe, and Japan, 2007-2017
- 2. Diagnosed and Drug-Treated Cases of Obsessive-Compulsive Disorder in
the United States, Europe, and Japan, 2007
- 3. Treatment Algorithm for Obsessive-Compulsive Disorder
- 4. SSRI Action at the Serotonergic Synapse
- 5. Market Share of Leading Companies in the U.S. Obsessive-Compulsive
Disorder Market, 2007
|
